Anti-IL-12 antibodies and compositions
Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
1. A pen-injector containing a liquid pharmaceutical formulation comprising an effective amount of an isolated anti-IL-12 antibody having a heavy chain variable region and a light chain variable region, said heavy chain variable region comprising:
a heavy chain complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO:1,
a heavy chain complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO:2,
a heavy chain complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO:3,
said light chain variable region comprising:
a light chain complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO:4,
a light chain complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO:5, and
a light chain complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO:6.
2. The pen-injector according to claim 1 , wherein the liquid pharmaceutical formulation comprises histidine buffer, polysorbate 80 and sucrose.
3. The pen-injector according to claim 1 , wherein the pH is about 6.0.
4. The pen-injector according to claim 1 , wherein said effective amount is 45 mg of antibody.
5. The pen-injector according to claim 1 , wherein said effective amount is 90 mg of antibody.
6. A pen-injector containing a liquid pharmaceutical formulation comprising an effective amount of an isolated anti-IL-12 antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8.
7. The pen-injector according to claim 6 , wherein the liquid pharmaceutical formulation comprises histidine buffer, polysorbate 80 and sucrose.
8. The pen-injector according to claim 6 , wherein the pH is about 6.0.
9. The pen-injector according to claim 6 , wherein said effective amount is 45 mg of antibody.
10. The pen-injector according to claim 6 , wherein said effective amount is 90 mg of antibody.